Technical Analysis for MNKKQ - Mallinckrodt Plc

Grade Last Price % Change Price Change
D 0.33 -8.33% -0.0300
MNKKQ closed down 8.33 percent on Friday, March 5, 2021, on 40 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical MNKKQ trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Stochastic Buy Signal Bullish 0.00%
Doji - Bullish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish -8.33%
50 DMA Support Bullish -8.33%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -8.33%
Older End-of-Day Signals for MNKKQ ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Mallinckrodt Plc Description

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform, as well as Amitiza, a product for constipation. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; and SLN500, a ribonucleic acid technology therapy. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.


Classification

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Keywords: Medicine Clinical Medicine Pharmaceutical U.S. Bankruptcy Court Pain Pharmaceutical Products U.S. Bankruptcy Court For The District Of Delaware Pain Management Immunotherapy Multiple Sclerosis Burns Rheumatoid Arthritis Constipation Specialty Pharmacy Hepatic Encephalopathy Hepatorenal Syndrome Systemic Lupus Erythematosus

Is MNKKQ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.8
52 Week Low 0.0652
Average Volume 1,563,807
200-Day Moving Average 0.0000
50-Day Moving Average 0.3580
20-Day Moving Average 0.4220
10-Day Moving Average 0.3944
Average True Range 0.0750
ADX 23.08
+DI 16.3702
-DI 18.3107
Chandelier Exit (Long, 3 ATRs ) 0.4950
Chandelier Exit (Short, 3 ATRs ) 0.5252
Upper Bollinger Band 0.5127
Lower Bollinger Band 0.3313
Percent B (%b) -0.01
BandWidth 42.9858
MACD Line -0.0070
MACD Signal Line 0.0111
MACD Histogram -0.0181
Fundamentals Value
Market Cap 27.92 Million
Num Shares 84.6 Million
EPS
Price-to-Sales 0.01
Price-to-Book 0.02
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.4197
Resistance 3 (R3) 0.4197 0.3899 0.4048
Resistance 2 (R2) 0.3899 0.3670 0.3899 0.3998
Resistance 1 (R1) 0.3599 0.3529 0.3599 0.3599 0.3948
Pivot Point 0.3301 0.3301 0.3301 0.3301 0.3301
Support 1 (S1) 0.3001 0.3072 0.3001 0.3001 0.2652
Support 2 (S2) 0.2703 0.2931 0.2703 0.2602
Support 3 (S3) 0.2403 0.2703 0.2553
Support 4 (S4) 0.2403